Emyria Ltd has released a press release.
Placement completion and secondary trading notice
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Emyria
- Emyria completes $3m placement
- Emyria and UWA expand unique MDMA-inspired analogue library
- Emyria expands clinical sites for EMD-RX5 Phase 3 trial
- Emyria commences US preclinical program for MDMA library
- Appendix 4E and Annual Report
Later from Emyria
- Emyria accepted into National Institutes of Health Program
- Emyria receives $2.1M R&D tax incentive refund
- First dosing commenced for pivotal EMD-RX5 Phase 3 trial
- Appendix 4C - Quarterly
- Emyria welcomes dosing of first patient in Phase 3 anxiety trial
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria